Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations

v3.22.1
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue    
Product revenue, net $ 20,796 $ 10,719
Collaboration revenue 577 800
Revenue - related party 52 68
Other revenue 2,500  
Net revenue 23,925 11,587
Operating expenses    
Cost of goods sold - product revenue 8,203 3,908
Research and development 36,722 20,028
Research and development - licenses acquired   126
Selling, general and administrative 26,270 17,542
Total operating expenses 71,195 41,604
Loss from operations (47,270) (30,017)
Other income (expense)    
Interest income 142 227
Interest expense and financing fee (2,350) (2,189)
Change in fair value of investments 0 5,913
Total other income (expense) (2,208) 3,951
Net loss (49,478) (26,066)
Net loss attributable to non-controlling interests 33,718 17,244
Net loss attributable to common stockholders $ (15,760) $ (8,822)
Net loss per common share - basic $ (0.57) $ (0.32)
Net loss per common share - diluted   (0.32)
Net loss per common share attributable to non-controlling interests - basic (0.39) (0.21)
Net loss per common share attributable to non-controlling interests - diluted (0.39) (0.21)
Net income (loss) per common share attributable to common stockholders - basic (0.18) (0.11)
Net income (loss) per common share attributable to common stockholders - diluted $ (0.18) $ (0.11)
Weighted average common shares outstanding - basic 86,255,142 80,851,671
Weighted average common shares outstanding - diluted 86,255,142 80,851,671